Importantly, since silencing GSK-3α alone reduces AR activity without activating NFκB, our results support the case for the development and sequential use of isoform-specific GSK-3 inhibitors [53] to treat different stages of PCa. The gene discussed is NFKB1; the disease is posterior cortical atrophy.